Ovarian Cancer Trial, Not Yet Recruiting NCT07586449 Sponsor: Zhejiang Cancer Hospital Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Not Yet Recruiting

NCT07586449
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are willing to give their written agreement to take part in the study voluntarily.
  • People who have been diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, confirmed through laboratory testing of tissue or fluid samples.
  • People who are 18 years of age or older.
  • People whose doctor has determined that treatment with senaparib (either on its own or combined with another treatment) would be appropriate for them.
  • People who are capable of becoming pregnant must use effective birth control throughout the study and for 90 days after the last dose of senaparib.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who are pregnant or currently breastfeeding.
  • People who are already taking part in another research study that involves any intervention beyond standard everyday clinical care.
  • People whose doctor determines there are other reasons that make joining the study unsuitable (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86 138 5806 5156

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Zhejiang Cancer Hospital
Registry
ClinicalTrials.gov
Start date
10 June 2026
Est. completion
31 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence and severity of Treatment-Related Adverse Events (TRAEs) according to NCI CTCAE v5.0

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov